Altimmune, Inc. (NASDAQ: ALT) reported Q2 EPS of ($0.42), $0.08 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $8 thousand versus the consensus estimate of $866.67 thousand.

For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.